CALGB/SWOG 80405: Genome-Wide Association Study of Patients with Advanced or Metastatic Colorectal Cancer Treated with First-Line Chemotherapy Combined with Cetuximab and/or Bevacizumab

Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial

A. Venook, D. Niedzwiecki, H. Lenz, et al.. (2017). JAMA. Cited 773 times. https://doi.org/10.1001/jama.2017.7105

Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance)

F. Innocenti, A. Sibley, Sushant A. Patil, et al.. (2020). Clinical Cancer Research. Cited 16 times. https://doi.org/10.1158/1078-0432.CCR-20-2021

Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance)

Megan Li, Flora Mulkey, Chen Jiang, et al.. (2018). Clinical Cancer Research. Cited 15 times. https://doi.org/10.1158/1078-0432.CCR-17-1523

Plasma protein markers in advanced or metastatic colorectal cancer patients receiving chemotherapy with bevacizumab or cetuximab: Results from CALGB 80405 (Alliance).

A. Nixon, A. Sibley, Yingmiao Liu, et al.. (2021). Clinical cancer research : an official journal of the American Association for Cancer Research. Cited 15 times. https://doi.org/10.1158/1078-0432.CCR-21-2389

Genome‐wide association studies of survival in 1520 cancer patients treated with bevacizumab‐containing regimens

J. Quintanilha, Jin Wang, A. Sibley, et al.. (2021). International Journal of Cancer. Cited 8 times. https://doi.org/10.1002/ijc.33810